Biogen/Ionis ALS Therapy Tofersen is Getting FDA Priority Review

The FDA is granting the Biogen/Ionis ALS therapy drug tofersen, specific to SOD1 ALS, priority review an should have a decision by January 25th, 2023. This review is sped up to 6 months, compared to a 10 month review.


For more information regarding the priority review and tofersen, check out the press release: https://seekingalpha.com/news/3860495-biogenionis-als-therapy-tofersen-gets-fda-priority-review?source=apple_news&utm_medium=referral